The 3-year EFS for younger patients (≤60 years) treated with ibrutinib plus R-CHOP was 100% in the MCD and N1 subtypes, whereas survival was markedly lower in patients receiving R-CHOP alone (42.9% and 50%, respectively).71 Zhao et al. conducted a phase II trial to evaluate the efficacy of genetic subtype-guided targeted agents (ibrutinib for MCD-like and BN2-like, lenalidomide for N1-like and NOS, decitabine for TP53 mutations, and tucidinostat for EZB-like) combined with R-CHOP (R-CHOP-X) in newly diagnosed intermediate- or high-risk DLBCL patients. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.